Gynecologic Cancer News

Higher levels of anxiety and depression among patients with cancer appeared to be associated with more severe disease-related pain, according to study results scheduled for presentation at Supportive Care in Oncology Symposium.

Cancer-related nonprofit organizations play a crucial role in supporting medical research and patient advocacy, generating nearly $6 billion in revenue annually, according to a study published in Journal of the National Comprehensive Cancer Network.

Women who underwent combined breast, plastic reconstructive and gynecologic surgery exhibited higher rates of postoperative complications, readmission and reoperation than women who underwent breast surgery alone, according to study results published in Breast Journal.

A combination of nivolumab and bevacizumab appeared safe and induced responses among women with relapsed ovarian cancer, according to results of a single-arm, phase 2 trial published in JAMA Oncology.

Uncontained power morcellation appeared associated with increased risk for mortality among women with occult uterine sarcoma, according to study results published in Journal of Clinical Oncology.

The FDA granted fast track designation to navicixizumab for the treatment of women with heavily pretreated high-grade ovarian, primary peritoneal or fallopian tube cancer.

Avelumab induced promising activity among women with mismatch repair-deficient endometrial cancer regardless of PD-L1 status, according to results of a prospective phase 2 trial published in Journal of Clinical Oncology.

BARCELONA, Spain — Nivolumab in combination with ipilimumab conferred clinical benefit for women with recurrent or metastatic cervical cancer regardless of PD-L1 status, according to results of the randomized phase 1b/phase 2 CheckMate 358 study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — The addition of the ATR kinase inhibitor M6620 to gemcitabine extended PFS without additional toxicity among patients with platinum-resistant, high-grade serous ovarian cancer, according to randomized phase 2 study results presented at European Society of Medical Oncology Congress.

BARCELONA, Spain — The addition of veliparib to frontline chemotherapy followed by maintenance with veliparib monotherapy significantly prolonged PFS among women with newly diagnosed, high-grade serous ovarian carcinoma, according to results of the randomized phase 3 VELIA/GOG-3005 trial presented at European Society for Medical Oncology Congress.